
    
      This is an open-label, Phase 1/2 study of seviteronel in subjects with TNBC or ER +/HER2
      normal unresectable locally advanced breast cancer. Only women will be enrolled in Phase 1
      and both men and women enrolled into their respective cohorts in Phase 2. There will be a
      dose confirmation Phase 1 portion of the study to establish the recommended Phase 2 dose
      (RP2D) for women with breast cancer using a non-stratified, combined cohort of women with
      TNBC or ER+ BC. Cohort expansion will occur in Phase 2 at the RP2D confirmed/established in
      Phase 1 using separate TNBC and ER+ cohorts. The Phase 2 portion of the study is divided into
      three parallel cohorts:

      Cohort 1: Female TNBC Subjects Cohort 2: Female ER+ Subjects Cohort 3: Male ER+ BC or TNBC
      Subjects
    
  